18 completed, 7 terminated, 3 unknown, 2 active not recruiting. 32 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 18, Terminated 7, Unknown 3, Active not recruiting 2, Not yet recruiting 2 |
| Phase 2 | 1 | Completed 1 |
Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) Asciminib, Nilotinib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 568 | 2022-11-21 | 2026-08-26 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| Nilotinib for First-line Newly Diagnosed CML-CP Patients Nilotinib - Chronic Myeloid Leukemia, Chronic Phase, Nilotinib | Phase 3 | Unknown | Shenzhen Second People's Hospital | 100 | 2019-06-01 | 2022-03-16 |
| Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase | Phase 3 | Terminated | Hamad Medical Corporation | 10 | 2017-08-03 | 2019-01-23 |
| A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults Nilotinib, Methotrexate, Aracytine (Ara C) - Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 265 | 2016-04-01 | 2019-10-21 |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID - Chronic Phase Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 44 | 2015-12-31 | 2021-11-26 |
| Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib Nilotinib - Philadelphia Positive (Ph+) Chronic Myeloid Leukemia | Phase 3 | Terminated | Novartis Pharmaceuticals | 7 | 2015-12-17 | 2019-12-10 |
| Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response imatinib, nilotinib, dasatinib - Leukemia, Chronic Myeloid | Phase 3 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 229 | 2015-06-10 | 2024-08-13 |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) - Chronic Myeloid Leukemia | Phase 3 | Completed | Hospices Civils de Lyon | 200 | 2014-08-01 | 2025-10-02 |
| A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase Imatinib, Nilotinib - Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 225 | 2014-07-17 | 2019-08-19 |
| Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. Nilotinib - Philidelphia Positive Chronic Myeloid Leukaemia | Phase 3 | Terminated | Novartis Pharmaceuticals | 20 | 2014-07-07 | 2017-10-27 |
| An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years Imatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Terminated | Prof. Dr. Nikolas von Bubnoff | 14 | 2014-03-01 | 2019-12-02 |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. Nilotinib - Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | Phase 3 | Completed | Novartis Pharmaceuticals | 620 | 2013-04-15 | 2021-07-15 |
| Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance Imatinib and Nilotinib - Leukemia, Myeloid, Chronic, BCR-ABL Positive | Phase 3 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2012-10-01 | 2014-01-07 |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study Peginterferon α2b, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | University of Jena | 717 | 2012-08-24 | 2023-05-10 |
| Nilotinib in PH+, BCR-, ABL+ CML Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 109 | 2012-01-01 | 2018-08-06 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 421 | 2011-04-01 | 2016-03-03 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (24) · Leukemia (9) · Gastrointestinal Stromal Tumors (4) · Leukemia, Myeloid, Chronic-Phase (4) · Philadelphia Chromosome (4) · Bone Marrow Diseases (3) · Leukemia, Myeloid (3) · Bronchiolitis Obliterans Syndrome (2) · Hematologic Neoplasms (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Diseases (1) · Neoplasm Metastasis (1) · Neoplasms by Histologic Type (1)
Novartis Pharmaceuticals (18) · Ariad Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Enliven Therapeutics (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hamad Medical Corporation (1) · Hospices Civils de Lyon (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Prof. Dr. Nikolas von Bubnoff (1) · Seoul St. Mary's Hospital (1) · Shenzhen Second People's Hospital (1) · University of Jena (1)
Germany (11) · France (10) · Italy (10) · Canada (8) · China (8) · Czechia (8) · South Korea (8) · Argentina (7) · Brazil (7) · Spain (7) · Australia (6) · Mexico (6) · Russia (6) · United States (6) · Austria (5)
Andreas Hochhaus, Prof. MD (1) · Antoine Italiano (1) · Domenico Russo, Professor (1) · Dong-Wook Kim, MD, PhD (1) · Gianantonio Rosti (1) · Mohamed A Yassin (1) · Nikolas von Bubnoff, Professor (1)
PMID 17715389, PMID 20525993, PMID 21467546, PMID 21856226, PMID 22207416, PMID 23109697, PMID 23502220, PMID 24335106, PMID 24472814, PMID 24532039, PMID 24948656, PMID 25766724, PMID 25882987, PMID 26871197, PMID 27470600, PMID 27890073, PMID 28699641, PMID 32713836, PMID 34123791, PMID 34740331, PMID 36524980, PMID 38452207, PMID 38820078, PMID 41397287, PMID 42069411, PMID 42339511
2008 (3), 2009 (1), 2015 (1), 2017 (1), 2023 (1)